Liver cancer is the second most lethal cancer in the world with limited treatment options. Hepatocellular carcinoma (HCC), which accounts for more than 80% of all liver cancers, has had increasing global incidence over the past few years. There is an urgent need for novel and better therapeutic intervention for HCC patients. The JAK/STAT signaling pathway plays a multitude of important biological functions in both normal and malignant cells. In a subset of HCC, JAK/STAT signaling is aberrantly activated, leading to dysregulation of downstream target genes that controls survival, angiogenesis, stemness, immune surveillance, invasion and metastasis. In this review, we will focus on the role of JAK/STAT signaling in HCC and discuss the current clinical status of several JAK/STAT inhibitors.
We demonstrate that in human HCCs with deregulated expression of purine metabolic enzymes, targeting purine metabolism was effective in blocking tumor cell proliferation, leading to tumor shrinkage. Precise regulation of purine metabolic activity was coordinated by the activation status of a PI3K‐E2F1 axis, and potent suppression of purine metabolism via combinatorial targeting of PI3K and the purine synthetic rate‐limiting enzyme IMPDH resulted in enhanced efficacy in a pre‐clinical model. These data provide a strong basis for future precision‐medicine focused clinical trials targeting this tumor‐specific metabolic adaptation as a point of vulnerability in patients with HCC.
Comprehensive analysis of hepatocellular carcinoma 3D models revealed enhanced penetrative siRNA delivery by a nanodiamonds compared to liposomes. Nanodiamonds were able to improve siRNA's gene knockdown and anti-cancer effects in 3D tumor models.
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the world. Histone‐lysine N‐methyltransferase EHMT2 (also known as G9a) is a histone methyltransferase frequently overexpressed in many cancer types, including HCC. We showed that Myc‐driven liver tumours have a unique H3K9 methylation pattern with corresponding G9a overexpression. This phenomenon of increased G9a was further observed in our c‐Myc‐positive HCC patient‐derived xenografts. More importantly, we showed that HCC patients with higher c‐Myc and G9a expression levels portend a poorer survival with lower median survival months. We demonstrated that c‐Myc interacts with G9a in HCC and cooperates to regulate c‐Myc‐dependent gene repression. In addition, G9a stabilises c‐Myc to promote cancer development, contributing to the growth and invasive capacity in HCC. Furthermore, combination therapy between G9a and synthetic‐lethal target of c‐Myc, CDK9, demonstrates strong efficacy in patient‐derived avatars of Myc‐driven HCC. Our work suggests that targeting G9a could prove to be a potential therapeutic avenue for Myc‐driven liver cancer. This will increase our understanding of the underlying epigenetic mechanisms of aggressive tumour initiation and lead to improved therapeutic and diagnostic options for Myc‐driven hepatic tumours.
Deregulation of MYC is among the most frequent oncogenic drivers in hepatocellular carcinoma (HCC). Unfortunately, the clinical success of MYC‐targeted therapies is limited. Synthetic lethality offers an alternative therapeutic strategy by leveraging on vulnerabilities in tumors with MYC deregulation. While several synthetic lethal targets of MYC have been identified in HCC, the need to prioritize targets with the greatest therapeutic potential has been unmet. Here, we demonstrate that by pairing splice‐switch oligonucleotide (SSO) technologies with our phenotypic‐analytical hybrid multidrug interrogation platform, quadratic phenotypic optimization platform (QPOP), we can disrupt the functional expression of these targets in specific combinatorial tests to rapidly determine target–target interactions and rank synthetic lethality targets. Our SSO‐QPOP analyses revealed that simultaneous attenuation of CHK1 and BRD4 function is an effective combination specific in MYC‐deregulated HCC, successfully suppressing HCC progression in vitro. Pharmacological inhibitors of CHK1 and BRD4 further demonstrated its translational value by exhibiting synergistic interactions in patient‐derived xenograft organoid models of HCC harboring high levels of MYC deregulation. Collectively, our work demonstrates the capacity of SSO‐QPOP as a target prioritization tool in the drug development pipeline, as well as the therapeutic potential of CHK1 and BRD4 in MYC‐driven HCC.
Spalt-like transcription factor 4 (SALL4) is an oncofetal
protein
that has been identified to drive cancer progression in hepatocellular
carcinoma (HCC) and hematological malignancies. Furthermore, a high
SALL4 expression level is correlated to poor prognosis in these cancers.
However, SALL4 lacks well-structured small-molecule binding pockets,
making it difficult to design targeted inhibitors. SALL4-induced expression
of oxidative phosphorylation (OXPHOS) genes may serve as a therapeutically
targetable vulnerability in HCC through OXPHOS inhibition. Because
OXPHOS functions through a set of genes with intertumoral heterogeneous
expression, identifying therapeutic sensitivity to OXPHOS inhibitors
may not rely on a single clear biomarker. Here, we developed a workflow
that utilized molecular beacons, nucleic-acid-based, activatable sensors
with high specificity to the target mRNA, delivered by nanodiamonds,
to establish an artificial intelligence (AI)-assisted platform for
rapid evaluation of patient-specific drug sensitivity. Specifically,
when the HCC cells were treated with the nanodiamond-medicated OXPHOS
biosensor, high sensitivity and specificity of the sensor allowed
for improved identification of OXPHOS expression in cells. Assisted
by a trained convolutional neural network, drug sensitivity of cells
toward an OXPHOS inhibitor, IACS-010759, could be accurately predicted.
AI-assisted OXPHOS drug sensitivity assessment could be accomplished
within 1 day, enabling rapid and efficient clinical decision support
for HCC treatment. The work proposed here serves as a foundation for
the patient-based subtype-specific therapeutic research platform and
is well suited for precision medicine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.